zabofloxacin zabofloxacin zabofloxacin (dw-224a) is an investigational fluoroquinolone antibiotic for multidrug-resistant infections due to gram-positive bacteria. it also has activity against neisseria gonorrhoeae including strains that are resistant to other quinolone antibiotics. zabofloxacin names preferred iupac name 1-cyclopropyl-6-fluoro-7-octan-6-yl]-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid other names dw-224a identifiers cas number 219680-11-2 y 3d model (jsmol) interactive image chemspider 8128482 pubchem cid 9952872 unii lv66ba6v2g y inchi inchi=1s/c19h20fn5o4/c1-29-23-14-6-24(9-19(14)7-21-8-19)17-13(20)4-11-15(26)12(18(27)28)5-25(10-2-3-10)16(11)22-17/h4-5,10,21h,2-3,6-9h2,1h3,(h,27,28)/b23-14-key: znpoclhdjcazah-ucqkpksfsa-ninchi=1/c19h20fn5o4/c1-29-23-14-6-24(9-19(14)7-21-8-19)17-13(20)4-11-15(26)12(18(27)28)5-25(10-2-3-10)16(11)22-17/h4-5,10,21h,2-3,6-9h2,1h3,(h,27,28)/b23-14-key: znpoclhdjcazah-ucqkpksfbl smiles fc1c(nc2c(c1)c(=o)c(\c(=o)o)=c/n2c3cc3)n5c\c(=n\oc)c4(cnc4)c5 properties chemical formula c19h20fn5o4 molar mass 401.392 except where otherwise noted, data are given for materials in their standard state (at 25 °c , 100 kpa). infobox references zabofloxacin was discovered by dong wha pharmaceuticals and licensed to pacific beach biosciences for development. a double-blind, three-arm clinical study of the drug began in march 2010.